Based on the PDS Biotechnology Corp stock forecast from 2 analysts, the average analyst target price for PDS Biotechnology Corp is USD 5.75 over the next 12 months. PDS Biotechnology Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of PDS Biotechnology Corp is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, PDS Biotechnology Corp’s stock price was USD 1.11. PDS Biotechnology Corp’s stock price has changed by +18.70% over the past week, -9.76% over the past month and -60.64% over the last year.
No recent analyst target price found for PDS Biotechnology Corp
No recent average analyst rating found for PDS Biotechnology Corp
Company Overview PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey. Read Less
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment f...Read More
Frequently Asked Questions About PDS Biotechnology Corp (PDSB) Stock
Based on ratings from 2 analysts PDS Biotechnology Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on PDSB's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for PDSB is USD 5.75 over the next 12 months. The maximum analyst target price is USD 7 while the minimum anlayst target price is USD 4.5.
PDSB stock's Price/Earning ratio is 24.96.
Our analysis grades PDSB stock's Price / Earning ratio at F. This means that PDSB stock's Price/Earning ratio is above 73% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this PDSB may be a overvalued for its sector.
The last closing price of PDSB's stock was USD 1.11.
The most recent market capitalization for PDSB is USD 0.05B.
Based on targets from 2 analysts, the average taret price for PDSB is projected at USD 5.75 over the next 12 months.
This means that PDSB's stock price may go up by +418.02% over the next 12 months.
We can't find any ETFs which contains PDS Biotechnology Corp's stock.
As per our most recent records PDS Biotechnology Corp has 24 Employees.
PDS Biotechnology Corp's registered address is 303A College Road East, Princeton, NJ, United States, 08540.
You can get more information about it from PDS Biotechnology Corp's website at https://www.pdsbiotech.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About PDS Biotechnology Corp (PDSB) Stock
Based on ratings from 2 analysts PDS Biotechnology Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on PDSB's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for PDSB is USD 5.75 over the next 12 months. The maximum analyst target price is USD 7 while the minimum anlayst target price is USD 4.5.
PDSB stock's Price/Earning ratio is 24.96.
Our analysis grades PDSB stock's Price / Earning ratio at F. This means that PDSB stock's Price/Earning ratio is above 73% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this PDSB may be a overvalued for its sector.
The last closing price of PDSB's stock was USD 1.11.
The most recent market capitalization for PDSB is USD 0.05B.
Based on targets from 2 analysts, the average taret price for PDSB is projected at USD 5.75 over the next 12 months.
This means that PDSB's stock price may go up by +418.02% over the next 12 months.
We can't find any ETFs which contains PDS Biotechnology Corp's stock.
As per our most recent records PDS Biotechnology Corp has 24 Employees.
PDS Biotechnology Corp's registered address is 303A College Road East, Princeton, NJ, United States, 08540.
You can get more information about it from PDS Biotechnology Corp's website at https://www.pdsbiotech.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PDSB !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
